SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Apple Turns 50: From Garage Startup to AI Crossroads 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
ROCKVILLE, Md., Sept. 07, 2016 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 in New York.
A live webcast of REGENXBIO’s presentation is scheduled to begin at 12:55 p.m. ET and will feature a fireside chat with Kenneth T. Mills, President and Chief Executive Officer. The live webcast can be accessed in the Investors section of REGENXBIO’s website at www.regenxbio.com. An archived replay of the webcast will be available on the same website for approximately 30 days following the presentation.
REGENXBIO representatives will also attend the Bank of America Merrill Lynch Global Healthcare Conference on Friday, September 16, 2016 in London to meet one-on-one with investors, analysts and other potential corporate partners.
About REGENXBIO
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform licensees. As of June 30, 2016, REGENXBIO's NAV Technology Platform was being applied in the development of 29 product candidates for a variety of diseases, including five internally developed candidates and 24 partnered candidates developed by REGENXBIO's licensees.
CONTACT: Investors Elizabeth Broder, 646-378-2945 [email protected] Media Laura Bagby, 312-448-8098 [email protected]
